Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML

Starting soon · Early Phase 1

Conditions studied: R/R AML

In brief

The purpose of this clinical trial is to evaluate the safety and efficacy of CAR-ITNK cells therapy targeting CD70 and CLL1 in participants with relapsed/refractory Acute Myeloid Leukemia. Participants will receive a single infusion of CAR-ITNK cell therapy targeting CD70 and CLL1 and complete follow-ups over the next three years.

Key facts

Study ID

NCT07336875

Run by

Tongji Hospital

People needed

30

Starts

2026-02-28

Expected to finish

2029-02-28

Last updated by the study team

2026-01-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient or their legal guardian voluntarily participates and has signed the informed consent form.
• Age between 18 and 75 years old (inclusive), with no gender restrictions. 3. Diagnosed as having refractory/relapsed acute myeloid leukemia, meeting one of the following criteria:
• . Reappearance of leukemic cells in peripheral blood after achieving complete remission, or bone marrow blast count > 5% (excluding other causes such as bone marrow reconstitution post-consolidation chemotherapy), or the presence of extramedullary leukemic cell infiltration.
• . Ineligible for bone marrow transplantation, or have undergone bone marrow transplantation but failed to achieve long-term remission.
• Expression of both CLL-1 and CD70 targets is confirmed as positive by flow cytometry.
• Patients must have good major organ function:
• . Liver function: ALT/AST < 3 times the upper limit of normal (ULN) and total bilirubin ≤ 34.2 μmol/L.
• . Kidney function: Creatinine clearance rate (Cockcroft-Gault method) ≥ 60 mL/min.
• . Lung function: Oxygen saturation ≥ 95%, with no active pulmonary infection.
• . Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%; no significant pericardial effusion, and no clinically significant ECG abnormalities.
• Women of childbearing age must have a negative urine/blood pregnancy test during screening and agree to use contraceptive measures for at least 1 year after infusion. Male subjects with reproductive capacity must agree to use effective barrier contraception for at least 1 year after infusion.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3. 8. Expected life expectancy greater than 3 months. 9. The patient is willing to cooperate with the collection of peripheral blood mononuclear cells, medical examinations, and regular follow-up visits.

You may not qualify if…

• The patient will be excluded if meeting any of the following criteria:
• Women who are pregnant or breastfeeding.
• Presence of uncontrolled fungal, bacterial, treponemal (e.g., syphilis), viral, or other infections.
• Active hepatitis B (Hepatitis B virus DNA > 500 IU/mL) or a positive Hepatitis C virus RNA (HCV-RNA) test.
• Human Immunodeficiency Virus (HIV) infection, or syphilis infection.
• Previously received any form of gene therapy.
• The patient has an allergic constitution or is allergic to macromolecular biologics such as antibodies or cytokines.
• History of clinically significant central nervous system diseases, such as: epilepsy, hemiparesis, aphasia, stroke, severe brain trauma, dementia, Parkinson's disease, cerebellar diseases, or organic brain syndromes.
• Uncontrolled psychiatric illness.
• A history of drug abuse/addiction.
• Use of prohibited medications:
• (1). Hormones: Use of corticosteroids (prednisone ≥ 2 mg/kg or equivalent > 20 mg/day) within 2 weeks prior to cell collection. Recent or ongoing use of inhaled, topical, or non-absorbable steroids is not an exclusion criterion.
• (2). Radiotherapy/Chemotherapy:Receipt of radiotherapy or salvage chemotherapy for the study disease within 3 weeks prior to cell collection.
• (3). Use of immunosuppressive agents within 4 weeks prior to cell collection. (4). Participation in another clinical trial or receipt of a major non-diagnostic surgical procedure within 4 weeks prior to cell collection.
• (5). Use of alemtuzumab within 6 months, or cladribine/clofarabine within 3 months, prior to cell collection.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.